New hope for tough thyroid cancers? cabozantinib trial shows promise
NCT ID NCT05660954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the drug cabozantinib in 41 adults with advanced differentiated thyroid cancer that no longer responds to radioactive iodine treatment. Participants took a 60 mg pill daily until their cancer worsened or side effects became too severe. The main goal was to understand how the drug affects certain biomarkers in the blood and to measure tumor shrinkage.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib
What this could lead to
If successful, this could provide a new treatment option for patients with advanced thyroid cancer that no longer responds to radioactive iodine.
What could go wrong
This is a small, early-phase trial with only 41 participants and no comparison group, so results may not apply broadly. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Asistencial Universitario de Salamanca
Salamanca, Salamanca, 37007, Spain
-
Complexo Hospitalario Universitario A Coruña
A Coruña, A Coruña, 15006, Spain
-
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036, Spain
-
Hospital Clínico San Carlos
Madrid, Madrid, 28040, Spain
-
Hospital General Universitario Morales Meseguer
Murcia, Murcia, 30008, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, Madrid, 28034, Spain
-
Hospital Universitario Vall d'Hebron
Barcelona, Barcelona, 08035, Spain